Transcriptomic characterization of plasma exosomes
Closed Special Notice Posted
- Solicitation number
- NHGRI-09000
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health National Human Genome Research Institute issued a special notice on August 20, 2026 for consumables and reagents to process 650 plasma exosomal RNA samples for next-generation sequencing, with a response deadline of August 31, 2026. The products will be supplied by New England Biolabs and are specified for compatibility with the Illumina sequencing platform available through NHGRI's core laboratory. The Center for Research on Genomics and Global Health will use these materials to characterize gene expression profiles of plasma exosomes in order to investigate the pathophysiology of cardiometabolic diseases and associated traits across diverse populations. The project aims to identify novel biomarkers and elucidate disease mechanisms through molecular analysis of plasma collected via minimally invasive methods. The acquisition focuses on laboratory consumables and reagent supplies with technical specifications and quantities tailored to accommodate processing of the defined sample set.
Notice text
The primary purpose of this acquisition is to obtain consumables and reagents essential for processing 650 plasma exosomal RNA samples for next generation sequencing. The Center for Research on Genomics and Global employs various molecular biology techniques to investigate the pathophysiology of cardiometabolic diseases and associated traits across diverse populations. This project aims to characterize the gene expression profile of plasma exosomes, which are implicated in several diseases. Plasma, a biological fluid collected via minimally invasive methods, serves as an indicator of health and disease status. Molecular analysis of plasma may further elucidate disease mechanisms and facilitate the discovery of novel biomarkers. Consumables and reagents supplied by New England Biolabs (NEB) are utilized in generating all necessary products for sequencing on the Illumina platform, the system currently available to NHGRI investigators through the core laboratory supporting this ongoing project.
Files
| File | Type | Posted |
|---|---|---|
| SOW_ NEB_PCA_NHGRI_09000.docx | DOCX document | |
| PCA-NHGRI-09000 NOI.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity